Adriamycin pfs and Neoplasm progression - a phase IV clinical study of FDA data

Summary:

Neoplasm progression is reported as a side effect among people who take Adriamycin pfs (doxorubicin hydrochloride), especially for people who are female, 50-59 old, have been taking the drug for 1 - 6 months also take Cytoxan, and have Metastases to bone.

The phase IV clinical study analyzes which people have Neoplasm progression when taking Adriamycin pfs. It is created by eHealthMe based on reports of 6,484 people who have side effects when taking Adriamycin pfs from the FDA, and is updated regularly.

What is Adriamycin pfs?

Adriamycin pfs has active ingredients of doxorubicin hydrochloride. eHealthMe is studying from 6,495 Adriamycin pfs users. Check the latest studies of Adriamycin pfs.

What is Neoplasm progression?

Neoplasm progression (growth of tumour) is found to be associated with 1,067 drugs and 915 conditions by eHealthMe. Check the latest studies of Neoplasm progression.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 31, 2026

6,484 people reported to have side effects when taking Adriamycin pfs.
Among them, 73 people (1.13%) have Neoplasm progression.

Could Adriamycin pfs cause Neoplasm progression?

Among these 73 people:

How long have people been on Adriamycin pfs when they have Neoplasm progression? *

What is the gender of people who have Neoplasm progression when taking Adriamycin pfs? *

female: 95.89 %
male: 4.11 %

What is the age of people who have Neoplasm progression when taking Adriamycin pfs? *

What are other drugs people take besides Adriamycin pfs? *

What are other side effects people have besides Neoplasm progression? *

Neoplasm Malignant (cancer tumour): 66 people, 90.41%
Osteonecrosis Of Jaw (death of bone of jaw): 65 people, 89.04%
Pain: 64 people, 87.67%
Stress And Anxiety: 55 people, 75.34%
Osteoarthritis (a joint disease caused by cartilage loss in a joint): 46 people, 63.01%
Injury: 46 people, 63.01%
Back Pain: 39 people, 53.42%
Anhedonia (inability to experience pleasure from activities usually found enjoyable): 39 people, 53.42%
Atelectasis (partial or complete collapse of the lung): 38 people, 52.05%
Anaemia (lack of blood): 38 people, 52.05%

What are the existing conditions these people have? *

Metastases To Bone (cancer spreads to bone): 35 people, 47.95%
Breast Cancer: 20 people, 27.40%
Pain In Jaw: 5 people, 6.85%
Multiple Myeloma (cancer of the plasma cells): 3 people, 4.11%
Breast Cancer Metastatic: 3 people, 4.11%
Non-Hodgkin's Lymphoma (malignant (cancer) cells form in the lymph system): 2 people, 2.74%
Metastasis (spreadable cancer to other organ from origin): 1 person, 1.37%
Menopausal Symptoms: 1 person, 1.37%
Malignant Fibrous Histiocytoma (a cancer tumour of uncertain origin that arises both in soft tissue and bone): 1 person, 1.37%
Hypercalcaemia Of Malignancy (elevated calcium (ca+) level in the blood with cancer): 1 person, 1.37%

* Approximation only. Some reports may have incomplete information.

Do you take Adriamycin pfs and have Neoplasm progression?

- Check whether Neoplasm progression is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Adriamycin pfs:

Adriamycin pfs (6,495 reports)

Browse all side effects of Adriamycin pfs:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Neoplasm progression:

Neoplasm progression (1,067 drugs)

Browse all the conditions that are associated with Neoplasm progression:

Neoplasm progression (915 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on doxorubicin hydrochloride (the active ingredients of Adriamycin pfs) and Adriamycin pfs (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.